Medical Developments International Limited · ASX:MVP
Medical Developments International — Investor Presentation (September 2015)
44 slides from Medical Developments International's investor presentation, Sep 18, 2015
Slide 1: Medical Developments International Update
For personal use only Medical Developments International Update
Slide 2: Penthrox update
For personal use only PENTHROX update
Slide 3: Penthrox update: Europe
Penthrox update Europe For personal use only MVP signed a major distribution deal in Europe with Mundipharma. This complements our distribution deal already done with Galen for the UK & Northern Ireland. Collectively we now have full sales & marketing coverage for Europe and extended countries.
Slide 4: Europe - Mundipharma
Penthrox update Europe - Mundipharma For personal use only Mundipharma / (Purdue in the USA) is a top 20 global pharmaceutical company with sales estimated in excess of $2 billion. Mundipharma has a presence in 51 countries with more than 7800 employees across the world. Mundipharma is a world leade
Slide 5: Europe - Financial details
Penthrox update Europe - Financial details For personal use only Upfronts and milestone payments from Galen and Mundipharma are potentially worth more than AUD $80 million. Approximately AUD $10 million is due within the next 10 days from Mundipharma. We expect another AUD $15 million will be receiv
Slide 6: European sales
Penthrox update European sales For personal use only We expect peak sales to be in excess of 10,000,000 units per annum for Europe. Mundipharma is committed to develop the clinical indications for Penthrox in Europe and MVP will be able to participate in clinical trials that develop our markets. MVP
Slide 7: Manufacturing
Penthrox update Manufacturing For personal use only Our new manufacturing process has been assembled and tested. Commercial scale production runs have been completed. Product has been placed in stability trials and we expect validation of the process to be completed during FY16. When successful MVP
Slide 8: Intellectual property
Penthrox update Intellectual property For personal use only MVP has invested significant resources in developing intellectual property for Penthrox. As part of the development program, MVP filed 4 International Patents relating to Penthrox and its delivery systems. This IP will help secure and prote
Slide 9: Clinical development
Penthrox update Clinical development For personal use only MVP continues to invest in the clinical development of Penthrox. MVP recently completed a psychomotor function study at Royal Adelaide hospital which showed the use of Penthrox did not alter the patient’s ability to function such that: 1. A
Slide 10: Registrations and approvals
Penthrox update Registrations and approvals For personal use only We are waiting for the administrative processes and national phases of approvals in Europe to be complete. We are meeting with regulatory officials in Mexico during October and we are hopeful of an approval within the months following
Slide 11: Future
Penthrox update Future For personal use only Our ambition is to globalise Penthrox. We continue to develop and build a “world class” regulatory dossier which we will ultimately use to obtain approval to sell Penthrox in the USA and elsewhere in the world. MDI has spent almost $8million on developing
Slide 12: Financial update
For personal use only Financial update
Slide 13: Financial update
Financial update For personal use only Net Profit Total Earnings Before Net Profit After Tax Sales Interest and Tax After Tax $1.529m 24% 191% 75% up on prior period up on prior period up on prior period Bank Cash Flows From Debt * Operating Activities $2.46m * Net bank debt of nil when combined wit
Slide 14: Financial update: Results FY15
Financial update For personal use only Results FY15 FY14 Growth $’000 $’000 Sales 11,608 9,365 24% EBITDA 2,509 976 157% EBIT 2,251 776 191% NPAT 1,529 876 75%
Slide 15: Financial update: Results FY15
Financial update For personal use only Results FY15 FY14 Growth $’000 $’000 Sales of Penthrox 7,092 5,377 24% Sales of Medical Devices 4,078 3,503 16% Operating Expenses as a 48% 57% (16%) percentage of sales
Slide 16: Financial update – FY15 Cash Flow
Financial update – FY15 Cash Flow For personal use only
Slide 17: Medical Device update
For personal use only Medical Device update
Slide 18: Respiratory division
Medical Device update Respiratory division For personal use only Since 1985 MDI has invested significant R&D resources to improving the delivery of Asthma and COPD medication. In 2011 MDI launched the Space Chamber Plus® and the Compact Space Chamber Plus® in the Australian and International markets
Slide 19: Respiratory division
Medical Device update Respiratory division For personal use only In 2014 MDI completed the commissioning of its Respiratory Laboratory which it uses to develop and test new products. This Respiratory Laboratory is one of only a few in Australia and around the world. In 2015 MDI launched its range of
Slide 20: Respiratory division
Medical Device update Respiratory division For personal use only MDI offers a range of innovative world leading devices that help patients manage and take control of their asthma and COPD. • Space Chamber Plus® aerosol spacer • Space Chamber® re-usable • Compact Spacer Chamber Plus® • Breath-Alert®
Slide 21: Respiratory division
Medical Device update Respiratory division For personal use only MDI continues to develop its global footprint and expand its respiratory business. Sales are growing strongly. Currently we have business and are making sales in: Australia UK Singapore Hong Kong Canada Malaysia Belgium Germany Netherl
Slide 22: Medical Developments Global Strategy
For personal use only Medical Developments Global Strategy
Slide 23: Global Strategy
New and revised MDI materials and process Global Strategy (lowest cost producer and For personal use only significant IP)
Slide 24: Global Strategy
New and revised MDI materials and process Global Strategy (lowest cost producer and For personal use only significant IP) Product innovation (worlds best delivery devices and significant IP)
Slide 25: Global Strategy
New and revised MDI materials and process Global Strategy (lowest cost producer and For personal use only significant IP) Product innovation (worlds best delivery devices and significant IP) Regulatory Approval and new markets
Slide 26: Global Strategy
New and revised MDI materials and process Global Strategy (lowest cost producer and For personal use only significant IP) Product innovation (worlds best delivery devices and significant IP) Clinical trials (Commercial clinical studies to support marketing and product development) Regulatory Approva
Slide 27: Global Strategy
New and revised MDI materials and process Global Strategy (lowest cost producer and For personal use only significant IP) New Business Partners Product innovation (worlds best delivery devices and significant IP) Clinical trials (Commercial clinical studies to support marketing and product developme
Slide 28: Contact details
Contact details For personal use only HEAD OFFICE Factory 6 / 56 Smith Road PO Box 21 Springvale, VIC. 3171 Sandown Village, VIC. Australia Tel: +61 3 9547 1888 Fax: +61 3 9547 0262 Web: www.medicaldev.com
Slide 29: Forward looking statements
Forward looking statements For personal use only This document contains certain forward looking statements relating to Medical Development International’s business, which can be identified by the use of forward looking terminology such as “promising”, “plans”, “anticipated”, “will”, “project”, “beli
Slide 30: More about Penthrox
For personal use only More about Penthrox
Slide 31: Penthrox
Penthrox For personal use only Penthrox® • Inhalational analgesic • Demonstrated safety and efficacy profile • Only manufacturer in the world • Sold in Australia, N.Z, GCC South America, Eastern Europe & others • Manufactured in GMP compliant plant
Slide 32: Clinical application
Penthrox Clinical application For personal use only Painful procedures • Burn injuries Cosmetic Dentistry Surgery • Cutaneous excisions • Breaks, • Liquid nitrogen fractures and Military Consulting removals of skin- dislocations Rooms cancers, warts, etc • Abdomen pain • Invasive • Chest pain Ambula
Slide 33: Benefits to medical professionals
Penthrox Benefits to medical professionals For personal use only Rapid onset of Minimal waiting time before a painful procedure can be performed (3 minutes) and rapid pain relief when a patient is action treated for burns, trauma, etc. Inhaled self- Medical professionals can perform a procedure/atte
Slide 34: Benefits over Nitrous Oxide
Penthrox Benefits over Nitrous Oxide For personal use only Penthrox® does not effect vital signs; no clinical depression of respiration or circulation at low analgesic dosing. Self-administration, easy to use and administer. Compact and can be used in any location or situation. No risk of overdose.
Slide 35: Benefits over Morphine
Penthrox Benefits over Morphine For personal use only The benefits of using Penthrox® over Morphine are the same as detailed for Nitrous. In addition there are a number of specific benefits Penthrox has over Morphine which include: • Penthrox can be used on children, Morphine often cannot. • Penthro
Slide 36: More about Medical Developments International
For personal use only More about Medical Developments International
Slide 37: Vision
Vision For personal use only Medical Developments International (MDI) is a leading Emergency Medicine Company. Our aim is to: 1. Dominate the analgesic trauma and minor surgical procedures market domestically and internationally. 2. Dominate the Respiratory Medical Devices market domestically and in
Slide 38: Vision
Vision For personal use only MDI is working on and delivering two significant business opportunities. Both opportunities are “company making”. The risk profile of these opportunities is relatively low and well understood. Penthrox: We are well on the way to achieving the globalisation of Penthrox. W
Slide 39: Two world class opportunities: Penthrox
Two world class opportunities Penthrox For personal use only • Significant competitive advantages to other analgesics. • Fast, safe, rapid on-set, effective, cost-competitive, self administered. • No needles, non-opiate, easy to store & transport. • Building world class regulatory dossier to enable
Slide 40: Two world class opportunities: Respiratory Medical Devices
Two world class opportunities Respiratory Medical Devices For personal use only • Leading patented asthma & COPD medicine delivery devices. • Low resistance, more efficient medicine dosage delivery. • Won international tenders and major contracts in Canada, Germany and Australia to supply “Space Cha
Slide 41: MDI Medical: Rescue and resuscitation
MDI Medical Rescue and resuscitation For personal use only Our emergency medical equipment business has grown significantly since FY2011. MDI is the preferred supplier in a number of markets including: Ambulance, Non-emergency transport and Emergency First Aid. Various public and private health sect
Slide 42: MDI Medical
MDI Medical For personal use only Design, assemble and test a wide range of medical devices. ISO 13485 & GMP compliant assembly facilities. Over 30 devices in product portfolio. Focus on respiratory system and oxygen delivery. • Asthma management • Oxygen delivery and equipment • CO2 absorbers • Ven
Slide 43: MDI Veterinary
MDI Veterinary For personal use only Design, assemble and test a wide range of veterinary devices. Focus on anaesthesia and surgical consumables. Anaesthesia • Anaesthetic machines (closed circuit system) • Breathing circuits • Vaporisers
Slide 44: Medical Developments International END
IL, For personal use only Medical Developments International END
Medical Developments International — Investor Presentation (September 2015) on 6ix